Enlivex Reports $1.23 Billion Profit for Fiscal 2025 Driven by Dual Business Model

Enlivex Ltd. reported net income of $1.23 billion and diluted earnings per share of $25.48 for fiscal year 2025, with total treasury and treasury-related derivative assets reaching $2.31 billion. The company attributed much of its profitability during the year to appreciation in treasury and treasury-related derivative assets, highlighting the success of its distinctive dual business model. Enlivex concluded the fiscal year with total shareholders' equity of approximately $1.93 billion and maintained $30 million in cash, cash equivalents, and short-term investments in digital assets.

The company's dual-engine strategy differentiates it from traditional biotechnology firms by combining a clinical-stage immunotherapy platform focused on quality longevity therapeutics with a treasury model anchored in the Rain decentralized prediction markets protocol. This structure provides public market investors with exposure to emerging prediction markets infrastructure while simultaneously advancing clinical development programs aimed at improving healthspan and quality of life. Enlivex is currently progressing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with primary focus on age-related osteoarthritis.

Shai Novik, Executive Chairman of Enlivex, explained the strategic approach, stating that the clinical engine continues to advance with Allocetra™ and its potential to restore mobility and independence in aging populations. In parallel, the treasury engine establishes exposure to prediction markets infrastructure through the Rain protocol, creating a capital strategy designed to align long-term shareholder value with the growth of decentralized forecasting markets. Together, these two engines position Enlivex to pursue innovation in quality longevity therapeutics while developing an innovative treasury model for a public company, which contributed to strong profitability for Enlivex in 2025 based on the unrealized appreciation in the company's treasury and treasury-related derivative assets.

The company's financial performance demonstrates how unconventional business models can generate substantial returns in the biotechnology sector. By leveraging prediction markets through the Rain protocol at https://rainprotocol.org, Enlivex has created a treasury strategy that complements its core therapeutic development work. This approach represents a significant departure from traditional biotech financing models and could influence how other companies in the sector approach capital management and value creation. The earnings report provides detailed insights into how this dual strategy operates in practice and its financial implications for shareholders.